Back to top
more

Sucampo Pharmaceuticals, Inc. (SCMP)

(Real Time Quote from BATS)

$18.00 USD

18.00
NA

+0.05 (0.28%)

Updated Feb 13, 2018 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's Perjeta Gets FDA Nod for Post Surgery Breast Cancer

by Zacks Equity Research

Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence

    Regeneron in Strategic Immuno-Oncology Collaboration With ISA

    by Zacks Equity Research

    Regeneron Pharmaceuticals (REGN) and ISA Pharmaceuticals inked an agreement to advance ISA101 in combination with cemiplimab.

      Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate

      by Zacks Equity Research

      Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.

        Tirthankar Chakraborty headshot

        New Strong Buy Stocks for December 19th

        by Tirthankar Chakraborty

        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

          Tirthankar Chakraborty headshot

          New Strong Buy Stocks for December 14th

          by Tirthankar Chakraborty

          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

            Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

            by Zacks Equity Research

            Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

              3 Drug/Biotech Stocks Up More Than 10% This Week

              by Zacks Equity Research

              The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

                Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

                by Zacks Equity Research

                Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.

                  Novartis Announces Positive Data on Sickle Cell Disease Drug

                  by Zacks Equity Research

                  Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.

                    Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi

                    by Zacks Equity Research

                    Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi.

                      3 Drug/Biotech Stocks Up More Than 10% This Week

                      by Zacks Equity Research

                      The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

                        Roche Reports Tecentriq/Avastin Lung Cancer Study Data

                        by Zacks Equity Research

                        Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.

                          Sucampo Pharmaceuticals (SCMP) in Focus: Stock Moves 5.6% Higher

                          by Zacks Equity Research

                          Sucampo Pharmaceuticals(SCMP) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

                            Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success

                            by Zacks Equity Research

                            Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.

                              Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA

                              by Zacks Equity Research

                              Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.

                                AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

                                by Zacks Equity Research

                                AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

                                  Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

                                  by Zacks Equity Research

                                  Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

                                    Tirthankar Chakraborty headshot

                                    New Strong Buy Stocks for November 28th

                                    by Tirthankar Chakraborty

                                    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                                      Lilly Inks Deal to Include Dexcom Products in Diabetes System

                                      by Zacks Equity Research

                                      Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.

                                        Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

                                        by Zacks Equity Research

                                        Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.

                                          Valeant Closes Senior Note Offering, Reprices Term Loan

                                          by Zacks Equity Research

                                          Valeant (VRX) offered new debt and restructured old debt. The company is making efforts to repay its huge level of debt.

                                            Novartis (NVS) Receives EC Nod for Tasigna Label Expansion

                                            by Zacks Equity Research

                                            Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

                                              Alnylam's RNAi Candidate Gains Breakthrough Therapy Status

                                              by Zacks Equity Research

                                              Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.

                                                Roche Reports Positive Data From Tecentriq Combination Study

                                                by Zacks Equity Research

                                                Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

                                                  Galapagos' CF Candidate Shows Potential in Phase II Study

                                                  by Zacks Equity Research

                                                  Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.